A randomized phase ll study consisting S-1 + CDDP (SP) and Capecitabin + CDDP (XP) for adversed/metastatic gastric cancer with mesurable lesions and HER2 negative tumor (HERBIS-4A).
Phase of Trial: Phase II
Latest Information Update: 08 Jul 2016
At a glance
- Drugs Capecitabine (Primary) ; Cisplatin (Primary) ; Gimeracil/oteracil/tegafur (Primary)
- Indications Gastric cancer
- Focus Therapeutic Use
- Acronyms HERBIS-4A
- 30 Jun 2016 Status changed from recruiting to discontinued.
- 11 Dec 2011 Additional lead trial investigator identified as reported University Hospital Medical Information Network - Japan.
- 30 Nov 2011 New trial record